Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma

SEYHAN E. C., ALTIN S., ÇETİNKAYA E., SÖKÜCÜ S. N., Abali H., BÜYÜKPINARBAŞILI N., ...Daha Fazla

Annals of Thoracic and Cardiovascular Surgery, cilt.17, sa.2, ss.110-117, 2011 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.5761/atcs.oa.09.01526
  • Dergi Adı: Annals of Thoracic and Cardiovascular Surgery
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.110-117
  • Anahtar Kelimeler: excision repair cross complementation 1, immunochemistry, non-small cell lung carcinoma
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background and Aim: The effects of DNA repair pathway on survival were assessed by measuring the tumoral excision repair cross complementation 1 (ERCC1) expression in patients with resected non-small cell lung carcinoma (NSCLC). We aimed to determine the prognostic and predictive significance of ERCC1 in patients with completely resected NSCLC. Methods: Immunohistochemistry (IHC) was used to assess the expression of ERCC1 in resected lung tumor samples obtained from 98 patients untreated without pre- or post-operative chemotherapy and/or radiotherapy. The median H score was used as a cut-off for ERCC1 IHC. Univariate and multivariate analyses were performed for factors influencing patient survival. Results: The 5-year survival rates of patients for ERCC1 positive expression and ERCC1 negative expression were 76% and 49%, respectively; this difference was statistically significant (p = 0.004). Subsequent multivariate analysis suggested that ERCC1 expression (adjusted hazard ratio for death, 0.38; 95% CI, 0.18 to 0.78; p = 0.008) and pathological stage (2.2; 95% CI, 1.09 to 4.5; p = 0.027) were both independent prognostic factors. Conclusion: The level of ERCC1 expression in tumors a strong predictor of survival in resected NSCLC patients untreated without pre- or post-operative chemotherapy and/or radiotherapy. © 2011 The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery.